Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses

Proteome Science

Volumn 9, Issue , 2011, Pages

  Ivanova, M M ^a   Abner, S M ^a   Pierce, W M ^a   Klinge, C M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CALMODULIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR BETA; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HISTONE; TRYPSIN; VIMENTIN;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CARCINOMA CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; MALE; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEOMICS; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 80053341102     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-60     Document Type: Article

References (71)

1. Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Fioretta G, Schubert H, Vinh-Hung V, Soria J-C, Vlastos G, Rapiti E. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011, 117:1288-1295. 10.1002/cncr.25638, 21264820.
2. Dubey S, Siegfried JM, Traynor AM. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. The Lancet Oncology 2006, 7:416-424. 10.1016/S1470-2045(06)70693-3, 16648046.
3. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005, 70:372-381. 10.1016/j.steroids.2005.02.017, 15862820.
4. Ramchandran K, Patel JD. Sex Differences in Susceptibility to Carcinogens. Seminars in Oncology 2009, 36:516-523. 10.1053/j.seminoncol.2009.09.005, 19995643.
5. Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: A review. Gender Medicine 2010, 7:381-401. 10.1016/j.genm.2010.10.002, 21056866.
6. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994, 86:869-870. 10.1093/jnci/86.11.869, 8182770.
7. Siegfried JM, Hershberger PA, Stabile LP. Estrogen Receptor Signaling in Lung Cancer. Seminars in Oncology 2009, 36:524-531. 10.1053/j.seminoncol.2009.10.004, 2818861, 19995644.
8. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S-I, Kondo T, Sasano H. Intratumoral Estrogens and Estrogen Receptors in Human Non-Small Cell Lung Carcinoma. Clin Cancer Res 2008, 1078-0432. CCR-1007-1950.
9. Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Aquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor β-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clinical Cancer Research 2011,
10. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, Melamed J, Shapiro E, Garabedian MJ, Logan SK. Cell-specific Regulation of Androgen Receptor Phosphorylation in Vivo. J Biol Chem 2005, 280:40916-40924. 10.1074/jbc.M508442200, 16210317.
11. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510. 10.1126/science.277.5331.1508, 9278514.
12. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87:905-931. 10.1152/physrev.00026.2006, 17615392.
13. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000, 65:227-251. 10.1016/S0039-128X(99)00107-5, 10751636.
14. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Molecular and Cellular Endocrinology 2009, 308:32-38. 10.1016/j.mce.2009.03.026, 2847286, 19464786.
15. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002, 23:665-686. 10.1210/er.2001-0045, 12372846.
16. Levin ER. Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001, 91:1860-1867.
17. Levin ER. G Protein-Coupled Receptor 30: Estrogen Receptor or Collaborator?. Endocrinology 2009, 150:1563-1565. 10.1210/en.2008-1759, 2659267, 19307418.
18. Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM. Activity and intracellular location of estrogen receptors [alpha] and [beta] in human bronchial epithelial cells. Mol Cell Endocrinol 2009, 205:12-21.
19. Pedram A, Razandi M, Wallace DC, Levin ER. Functional Estrogen Receptors in the Mitochondria of Breast Cancer Cells. Mol Biol Cell 2006, 17:2125-2137. 10.1091/mbc.E05-11-1013, 1446071, 16495339.
20. Zhang G, Yanamala N, Lathrop KL, Zhang L, Klein-Seetharaman J, Srinivas H. Ligand-Independent Antiapoptotic Function of Estrogen Receptor-{beta} in Lung Cancer Cells. Mol Endocrinol 2010, 24:1737-1747. 10.1210/me.2010-0125, 2940472, 20660297.
21. Ivanova MM, Mazhawidza W, Dougherty SM, Klinge CM. Sex Differences in Estrogen Receptor Subcellular Location and Activity in Lung Adenocarcinoma Cells. Am J Respir Cell Mol Biol 2010, 42:320-330. 10.1165/rcmb.2009-0059OC, 2830404, 19556604.
22. Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocrine-Related Cancer 2006, 13:113-134. 10.1677/erc.1.01118, 1472635, 16601283.
23. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002, 188:125-140. 10.1016/S0303-7207(01)00750-X, 11911952.
24. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37:153-159. 10.1016/S0169-5002(02)00039-9, 12140138.
25. Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer RM. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994, 108:153-157.
26. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001, 285:340-347. 10.1006/bbrc.2001.5158, 11444848.
27. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S, Iwase H. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 2001, 163:207-212. 10.1016/S0304-3835(00)00680-7, 11165756.
28. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, et al. Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation. Clinical Cancer Research 2009, 15:5359-5368. 10.1158/1078-0432.CCR-09-0033, 2893045, 19706809.
29. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S. Nuclear Estrogen Receptor {beta} in Lung Cancer: Expression and Survival Differences by Sex. Clin Cancer Res 2005, 11:7280-7287. 10.1158/1078-0432.CCR-05-0498, 16243798.
30. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930. 10.1073/pnas.93.12.5925, 39164, 8650195.
31. Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PG, Katzenellenbogen BS. Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). J Biol Chem 2003, 278:4628-4638. 10.1074/jbc.M210066200, 12466272.
32. Johansson L, Bavner A, Thomsen JS, Farnegardh M, Gustafsson JA, Treuter E. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Mol Cell Biol 2000, 20:1124-1133. 10.1128/MCB.20.4.1124-1133.2000, 85230, 10648597.
33. Qi C, Zhu YT, Chang J, Yeldandi AV, Rao MS, Zhu YJ. Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2. Biochem Biophys Res Commun 2005, 328:393-398. 10.1016/j.bbrc.2004.12.187, 15694360.
34. Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan ST, Go NF, Hart CP, Schatz PJ. Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries. Mol Endocrinol 2000, 14:605-622. 10.1210/me.14.5.605, 10809226.
35. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ, Janne OA. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol Endocrinol 2000, 14:1986-2000. 10.1210/me.14.12.1986, 11117529.
36. Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA. Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 2001, 15:1929-1940. 10.1210/me.15.11.1929, 11682624.
37. Garcia Pedrero JM, Del Rio B, Martinez-Campa C, Muramatsu M, Lazo PS, Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 2002, 16:947-960. 10.1210/me.16.5.947, 11981030.
38. Aquila S, Sisci D, Gentile M, Middea E, Catalano S, Carpino A, Rago V, Ando S. Estrogen receptor (ER)alpha and ER beta are both expressed in human ejaculated spermatozoa: evidence of their direct interaction with phosphatidylinositol-3-OH kinase/Akt pathway. J Clin Endocrinol Metab 2004, 89:1443-1451. 10.1210/jc.2003-031681, 15001646.
39. Ivanova MM, Mattingly KA, Klinge CM. Estrogen receptor beta yield from baculovirus lytic infection is higher than from stably transformed Sf21 cells. Appl Microbiol Biotechnol 2007, 74:1256-1263. 10.1007/s00253-006-0784-9, 17318543.
40. Tarallo R, Bamundo A, Nassa G, Nola E, Paris O, Ambrosino C, Facchiano A, Baumann M, Nyman TA, Weisz A. Identification of proteins associated with ligand-activated estrogen receptor α in human breast cancer cell nuclei by tandem affinity purification and nano LC-MS/MS. Proteomics 2011, 11:172-179. 10.1002/pmic.201000217, 21182205.
41. Nassa G, Tarallo R, Ambrosino C, Bamundo A, Ferraro L, Paris O, Ravo M, Guzzi PH, Cannataro M, Baumann M, et al. A large set of estrogen receptor beta-interacting proteins identified by tandem affinity purification in hormone-responsive human breast cancer cell nuclei. Proteomics 2011, 11:159-165. 10.1002/pmic.201000344, 21182203.
42. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000, 60:5977-5983.
43. Yang S-H, Liu R, Perez EJ, Wen Y, Stevens SM, Valencia T, Brun-Zinkernagel A-M, Prokai L, Will Y, Dykens J, et al. Mitochondrial localization of estrogen receptor {beta}. PNAS 2004, 101:4130-4135. 10.1073/pnas.0306948101, 384706, 15024130.
44. Simpkins JW, Yang S-H, Sarkar SN, Pearce V. Estrogen actions on mitochondria--Physiological and pathological implications. Molecular and Cellular Endocrinology 2008, 290:51-59. 10.1016/j.mce.2008.04.013, 2737506, 18571833.
45. Yang S-H, Sarkar SN, Liu R, Perez EJ, Wang X, Wen Y, Yan L-J, Simpkins JW. Estrogen Receptor {beta} as a Mitochondrial Vulnerability Factor. J Biol Chem 2009, 284:9540-9548. 10.1074/jbc.M808246200, 2666606, 19189968.
46. Simpkins JW, Yi KD, Yang S-H, Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Biochimica et Biophysica Acta (BBA)-General Subjects 2010, 1800:1113-1120.
47. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF. Bioactivities, estrogen receptor interactions, and plasminogen activator- inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984, 44:112-119.
48. Skog S, He Q, Khoshnoud R, Fornander T, Rutqvist LE. Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour Biol 2004, 25:41-47. 10.1159/000077722, 15192311.
49. Durant ST, Nickoloff JA. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell Cycle 2005, 4:1216-1222. 10.4161/cc.4.9.2027, 16103751.
50. Wang CLA, Coluccio LM. New Insights into the Regulation of the Actin Cytoskeleton by Tropomyosin. International Review of Cell and Molecular Biology 2010, 281:91-128. Academic Press, Kwang WJ, 2923581, 20460184.
51. Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, Mutti L, Moro L. Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One 5:e14110.
52. Fan P, Wang J, Santen RJ, Yue W. Long-term Treatment with Tamoxifen Facilitates Translocation of Estrogen Receptor {alpha} out of the Nucleus and Enhances its Interaction with EGFR in MCF-7 Breast Cancer Cells. Cancer Res 2007, 67:1352-1360. 10.1158/0008-5472.CAN-06-1020, 17283173.
53. Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A. Phosphorylation of Activation Function-1 Regulates Proteasome-Dependent Nuclear Mobility and E6-Associated Protein Ubiquitin Ligase Recruitment to the Estrogen Receptor {beta}. Mol Endocrinol 2008, 22:317-330. 2346536, 17962381.
54. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008, 21(Suppl 2):S16-22.
55. Lo HW. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med 10:44-51.
56. Marquez DC, Lee J, Lin T, Pietras RJ. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 2001, 16:73-81. 10.1385/ENDO:16:2:073, 11887937.
57. Konishi A, Berk BC. Epidermal Growth Factor Receptor Transactivation Is Regulated by Glucose in Vascular Smooth Muscle Cells. Journal of Biological Chemistry 2003, 278:35049-35056. 10.1074/jbc.M304913200, 12829718.
58. Damstrup L, Wandahl Pedersen M, Bastholm L, Elling F, Skovgaard Poulsen H. Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer 2002, 97:7-14. 10.1002/ijc.1572, 11774237.
59. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001, 8:83-96. 10.1677/erc.0.0080083, 11397666.
60. Sengupta P, Bosis E, Nachliel E, Gutman M, Smith SO, Mihályné G, Zaitseva I, McLaughlin S. EGFR Juxtamembrane Domain, Membranes, and Calmodulin: Kinetics of Their Interaction. Biophysical Journal 2009, 96:4887-4895. 10.1016/j.bpj.2009.03.027, 2712057, 19527647.
61. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813. 10.1038/onc.2009.234, 2900381, 19684613.
62. Armour AA, Watkins CL. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev 2010, 19:186-196. 10.1183/09059180.00005110, 20956191.
63. Choi SH, Mendrola JM, Lemmon MA. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 2007, 26:1567-1576. 10.1038/sj.onc.1209957, 16953218.
64. Tornaletti S. DNA repair in mammalian cells: Transcription-coupled DNA repair: directing your effort where it's most needed. Cell Mol Life Sci 2009, 66:1010-1020. 10.1007/s00018-009-8738-x, 19153656.
65. Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol 2008, 9:958-970. 10.1038/nrm2549, 19023283.
66. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 2001, 98:9587-9592. 10.1073/pnas.171174298, 55496, 11493692.
67. Ma YX, Tomita Y, Fan S, Wu K, Tong Y, Zhao Z, Song LN, Goldberg ID, Rosen EM. Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 2005, 24:1831-1846. 10.1038/sj.onc.1208190, 15674350.
68. Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Semin Oncol 2009, 36:553-565. 10.1053/j.seminoncol.2009.09.004, 19995647.
69. Murphy CG, Moynahan ME. BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J 2010, 16:39-47. 10.1097/PPO.0b013e3181cf0204, 20164689.
70. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009, 4:461-487. 10.1146/annurev.pathol.3.121806.151422, 18954285.
71. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG, Tomita YA, Rosen EM. BRCA1 Regulates Acetylation and Ubiquitination of Estrogen Receptor-{alpha}. Mol Endocrinol 2010, 24:76-90. 10.1210/me.2009-0218, 2802901, 19887647.